Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
2017 · Breast Cancer Research and Treatment · 739 citations
https://doi.org/10.1007/s10549-017-4537-5
K
Kevin M. Chin
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
104
Papers
7.4K
Citations
29
h-index
45
i10-index
Kevin M. Chin is an academic researcher from Io Therapeutics (United States). The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & CAR-T cell therapy research & Immunotherapy and Immune Responses. The author has an h-index of 29, co-authored 89 publications.
ORCID: 0000-0002-5062-4159Papers by this author
worksAvelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial
2017 · The Lancet Oncology · 292 citations
https://doi.org/10.1016/s1470-2045(17)30239-5
Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma
2013 · British Journal of Cancer · 29 citations
https://doi.org/10.1038/bjc.2013.298
Abstract PS4-06-28: Initial clinical and pharmacology results from START-002: A phase 1b/2 clinical investigation of invikafusp alfa (STAR0602), a first-in-class dual T cell agonist, in combination with sacituzumab govitecan in patients with mTNBC or HR+/HER2- mBC
2026 · Clinical Cancer Research · 0 citations
https://doi.org/10.1158/1557-3265.sabcs25-ps4-06-28
PS5-09-16: A phase 1b/2 clinical investigation of invikafusp alfa (STAR0602), a first-in-class dual T-cell agonist, in combination with sacituzumab govitecan in patients with metastatic TNBC or HR+/HER2- MBC (START-002 trial)
2026 · Clinical Cancer Research · 0 citations
https://doi.org/10.1158/1557-3265.sabcs25-ps5-09-16
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat